|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM375413804 |
| 003 |
DE-627 |
| 005 |
20240925232508.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240726s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2024.110327
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1548.xml
|
| 035 |
|
|
|a (DE-627)NLM375413804
|
| 035 |
|
|
|a (NLM)39053866
|
| 035 |
|
|
|a (PII)S1521-6616(24)00436-4
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Watany, Mona M
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Methylation of Interleukin-1 receptor-associated kinase-3 and the risk of multiple sclerosis relapse/activity
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 16.08.2024
|
| 500 |
|
|
|a Date Revised 25.09.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2024. Published by Elsevier Inc.
|
| 520 |
|
|
|a This study retrospectively investigated the impact of interleukin-1 receptor-associated kinase-3 (IRAK-3/IRAK-M) silencing by methylation on the likelihood of multiple sclerosis (MS) activity. This cross-sectional study included 90 patients with MS: 45 with active disease (Group 1), 45 in remission (Group 2), and 45 healthy controls. The study included quantitation of IRAK-3 methylation index (MI%), IRAK-3 mRNA, and myeloid differentiation factor88 (MyD88) and assessment of NF-κB activity. IRAK-3 MI% was significantly higher in group 1 compared to group 2, accompanied by lower IRAK-3 mRNA expression, elevated circulating MyD88, and increased NF-κB activity. IRAK-3 MI% correlated negatively with its transcript and positively with MyD88 and NF-κB activity. A logistic regression model was created to predict active demyelination. The C-index was 0.924, which indicates a very strong prediction model. Within the limitations of current work, IRAK-3 methylation level seems to be a promising candidate biomarker for identifying MS patients at risk of relapse
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Active demyelination
|
| 650 |
|
4 |
|a IRAK-M
|
| 650 |
|
4 |
|a Interleukin-1 receptor-associated kinase-3 (IRAK-3)
|
| 650 |
|
4 |
|a Multiple sclerosis
|
| 650 |
|
4 |
|a Myeloid differentiation primary response 88 (MyD88)
|
| 650 |
|
4 |
|a Nuclear factor kappa-light-chain enhancer of activated B cells (NF-κB)
|
| 650 |
|
4 |
|a Relapse
|
| 650 |
|
7 |
|a Interleukin-1 Receptor-Associated Kinases
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.11.1
|2 NLM
|
| 650 |
|
7 |
|a Myeloid Differentiation Factor 88
|2 NLM
|
| 650 |
|
7 |
|a IRAK3 protein, human
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.11.1
|2 NLM
|
| 650 |
|
7 |
|a NF-kappa B
|2 NLM
|
| 650 |
|
7 |
|a MYD88 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Biomarkers
|2 NLM
|
| 650 |
|
7 |
|a RNA, Messenger
|2 NLM
|
| 700 |
1 |
|
|a Elhosary, Marwa M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a El-Horany, Hemat E
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a El-Horany, Mahmoud E
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 266(2024) vom: 24. Sept., Seite 110327
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:266
|g year:2024
|g day:24
|g month:09
|g pages:110327
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2024.110327
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 266
|j 2024
|b 24
|c 09
|h 110327
|